The Drug Controller General of India approved the manufacture and sale of the generic versions of the tablet in 91 developing countries.

The Drug Controller General of India approved the drug for manufacture and marketing. “Clinical studies have indicated that Sofosbuvir 400 mg, in combination with other agents, achieved very high cure rates, while shortening the duration of the treatment to as little as 12 weeks and reducing or completely eliminating the need for interferon injections, depending on the viral genotype,” said DRL.
DRL has a non-exclusive licence agreement with Gilead Sciences to manufacture and sell generic versions of its chronic Hepatitis C medicines in 91 developing countries.
Source-Medindia